"nci_id","nct_id","official_title","inclusion_indicaInclusionor","description","Text","Boolean",""
"NCI-2009-00336","NCT00392327","Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients","N/A","","","",""
"NCI-2009-00470","NCT00632853","Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide","N/A","","","",""
"NCI-2009-00595","NCT00719303","Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?","N/A","","","",""
"NCI-2009-00603","NCT00492778","A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus","N/A","","","",""
"NCI-2009-00817","NCT00001337","Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma","Inclusion","Human immunodeficiency virus (HIV) negative","HIV excluded OR HIV UNKNOWN","C15175 = NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2009-01057","NCT00576654","A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors","N/A","","","",""
"NCI-2011-00312","NCT01012817","A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy","Exclusion","Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive","HIV negative included:  Immunocompromised excluded (unless due to corticosteroid usage)","C14139 = NO OR (C14139=NO AND C211=YES) AND (C15175 = NO OR C15175=C17998) ","c14139:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-00878","NCT00956007","A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients  ","AIDS excluded; immunocompromised excluded","(C2851=NO) AND (C14139 = NO)","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-01915","NCT00887146","N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma","Exclusion","Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study","HIV positive and receiving antiretroviral therapy excluded;  HIV positive and no immunopromised eligible.  ","(C15175=NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO) OR (C15175 = YES AND C14139 = NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;c14139:affirmed;"
"NCI-2011-01972","NCT00983697","A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients","N/A","","","",""
"NCI-2011-01973","NCT00980954","Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy","Inclusion","Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)","HIV Negative or HIV positive and CD4>= 350 ","(C15175 = NO) OR (C15175 = C17998) OR (C15175 = YES AND C103810 >= 350 {cells}/mm3)","c15175:affirmed;c15175:affirmed;:affirmed;c103810:affirmative;measurement:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2011-01974","NCT00981656","A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients","AIDS excluded; immunocompromised excluded","(C2851 = NO) AND (C14139 = NO)","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-01975","NCT00980460","Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment","N/A","","","",""
"NCI-2011-01987","NCT01013649","A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma","Inclusion","Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed","HIV negative or HIV eligible if CD4 > 499 cell/mm3 and viral load < 50 copies/ml and HAART yes or no.  ","(C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C103810 > 499 {cells}/mm3 AND C92544 < 50 {copies}/ml)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c92544:affirmed;measurement:affirmed;c94631:affirmed;"
"NCI-2011-01992","NCT02085408","Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)","Inclusion","*B21Patients with known human immunodeficiency virus (HIV) infection are excluded                            *No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies","HIV positive excluded ","C15175 = NO OR C15175=C17998 ","c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-02000","NCT01042522","A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary","N/A","","","",""
"NCI-2011-02029","NCT01096368","Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years","N/A","","","",""
"NCI-2011-02034","NCT01118026","Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)","Inclusion","Patients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk","HIV positive if CD4 > 350 and on retrovirals.  ","(C15175 = NO)  OR (C15175=C17998) OR (C15175 = YES AND C103810 > 350 {cells}/mm3)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-02037","NCT01101451","Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy","N/A","","","",""
"NCI-2011-02073","NCT02589938","A Phase III Prospective Randomized Trial of Acupuncture for Treatment_x000D_ of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer","N/A","","","",""
"NCI-2011-02500","NCT01366144","An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible","HIV positive and antiretrovirals excluded;  HIV positive without AIDS defining diagnosis included  ","(C15175 = NO) OR (C15175=C17998) OR C15175 = YES AND C94631 = NO) OR (C15175 = YES AND C2851 =NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c2851:affirmed;c15220:affirmed;"
"NCI-2011-02515","NCT01051635","A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas","Exclusion","Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring antiretroviral therapy, ","HIV positive with antiretroviral therapy excluded ","(C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO)","c15175:negated;c15175:negated;c94631:affirmed;"
"NCI-2011-02539","NCT01226940","A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas","Exclusion","Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV positive with antiretroviral therapy excluded ","(C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO) ","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2011-02592","NCT01386385","A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)","Inclusion","Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study","HIV positive with antiretroviral therapy excluded ","(C15175 = NO) OR (C15175=C17998) OR (C14139=C17998) OR (C15175 = YES AND C94631 = NO)","c15175:affirmed;c15175:affirmed;"
"NCI-2011-02594","NCT01381718","A Phase II Placebo-Controlled Trial of Modafinil to Improve_x000D_ Neurocognitive Deficits in Children Treated for a Primary Brain Tumor","N/A","","","",""
"NCI-2011-02599","NCT01190930","Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)","N/A","","","",""
"NCI-2011-02611","NCT01231906","A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma","N/A","","","",""
"NCI-2011-02623","NCT01272037","A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer","N/A","","","",""
"NCI-2011-02660","NCT01275664","Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy","N/A","","","",""
"NCI-2011-02673","NCT01359592","A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)","Inclusion","Patients must not be known to be human immunodeficiency virus (HIV)-positive","","(C15175 = NO) OR (C15175=C17998)","c15175:affirmed;c15175:affirmed;"
"NCI-2011-02674","NCT01368588","Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients","AIDS excluded; immunocompromised excluded","(C2851 = NO) OR (C15175=C17998) AND (C14139 = NO)","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2011-03458","NCT01434316","Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors","N/A","","","",""
"NCI-2011-03797","NCT02883049","A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations","N/A","","","",""
"NCI-2012-00095","NCT01497444","Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC","N/A","","","",""
"NCI-2012-00105","NCT01503632","A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL","N/A","","","",""
"NCI-2012-00112","NCT01503086","Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study","N/A","","","",""
"NCI-2012-00234","NCT01515787","A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision","N/A","","","",""
"NCI-2012-00680","NCT01333046","Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma","Exclusion","PROCUREMENT: Patients with active human immunodeficiency virus (HIV) positive at time of procurement (can be pending at the time of blood draw)","HIV positive excluded ","(C15175 = NO) OR (C15175=C17998)","c15175:affirmed;c15175:affirmed;"
"NCI-2012-00707","NCT01556243","Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)","N/A","","","",""
"NCI-2012-00719","NCT01573442","Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias","N/A","","","",""
"NCI-2012-00860","NCT01587352","A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment","HIV positive on antiretrovirals included if CD4 >= 200","(C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C103810 > 200 {cells}/mm3)  ","c15175:affirmed;c15175:affirmed;c94631:affirmed;measurement:affirmed;measurement:affirmed;"
"NCI-2012-00864","NCT01585805","A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with  Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)","Exclusion","Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible","HIV positive and healthy and not immunocompromised included ","(C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C115935 = YES AND C14139 = NO)","c3096:affirmed;c141405:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2012-01040","NCT01638533","A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction","Inclusion","Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator","HIV positive eligible if CD4 > 250 ","(C15175 = NO) AND (C15175 = C17998) AND  (C15175 = YES AND   C103810 > 250 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c1428:affirmed;c947:affirmed;c97366:affirmed;c1609:affirmed;c17998:affirmed;c3095:affirmed;"
"NCI-2012-01695","NCT01775475","Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa","Inclusion","All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load > 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine [AZT]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment            *HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL   * WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load","antiviral therapy = Y and virological suppression =Y and immunocompromised =NO and viarl load > 400 copies/ML and antiretroviral therapy > 4 months and zidovudivine  = NO","HIV=YES AND C94631=YES AND C14139=NO AND C947=NO ","c94631:affirmed;c63350:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c94631:affirmed;c94631:affirmed;c947:affirmed;c947:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c92544:affirmed;c92544:affirmed;"
"NCI-2012-01712","NCT01695941","A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma","Exclusion/Inclusion","Exclusion:  HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible   Inclusion: Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ cluster of differentiation 4 (CD4)+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES and HAART=No) or (HIV=YES and HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO AND  CD4>= 300 {cells}/mm3 AND Viral Load=undetectable AND AIDS=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175  =YES and C94631=No) or (C15175 =YES and C94631=YES AND C111373=NO AND  C103810>= 300 {cells}/mm3 AND C92544=C111568 AND C2851=NO)","c94631:affirmed;c111374:affirmed;:affirmed;measurement:affirmed;:affirmed;measurement:affirmed;c92544:affirmed;c15175:affirmed;c15175:affirmed;c111374:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c92544:affirmed;c2851:affirmed;"
"NCI-2012-01964","NCT01595061","A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)","N/A","","","",""
"NCI-2012-01967","NCT01602666","Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)","N/A","","","",""
"NCI-2012-01977","NCT01622868","Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG","N/A","","","",""
"NCI-2012-01990","NCT01649089","Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (â‰¤ 2CM) Cervical Cancer","N/A","","","",""
"NCI-2012-01995","NCT01674140","Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.","Inclusion","Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>500 {cells}/mm3 AND HAART=NO) OR (C3096=NO) OR (C3096=Y AND Viral Load=0 {copies}/mm3 OR (C141405=NO) OR (C129452C=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>500 {cells}/mm3 AND C94631=NO) OR (C3096=NO) OR (C3096=Y AND C92544=C111568 {copies}/mm3 OR (C141405=NO) OR (C129452C=NO)","c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;c3095:affirmed;c3095:affirmed;c3095:affirmed;"
"NCI-2012-01998","NCT01668719","A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)","Inclusion","Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:  * Cluster of differentiation (CD)4 cells >= 500/mm^3  * Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART  * No zidovudine or stavudine as part of cART  * Patients who are HIV+ and do not meet all of these criteria are not eligible for this study","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND  CD4>=500 {cells}/mm3) AND ((HIV=YES AND cART=YES AND Viral Load<50 {copies}/mm3) OR (HIV =YES AND cART=NO AND Viral Load<25000 {copies}/mm3)) AND (Zidovudine=NO) AND (Stavudine=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND  C103810>=500 {cells}/mm3) AND ((C15175 =YES AND C94631=YES AND C92544<50 {copies}/mm3) OR (C15175 =YES AND C94631=NO AND C92544<25000 {copies}/mm3)) AND (C947=NO) AND (C1428=NO)","c15175:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c947:affirmed;c1428:affirmed;c15175:affirmed;"
"NCI-2012-02009","NCT01711541","Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck","Inclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible","HIV = NO or HIV = Y and HAART = NO","(C15175 = NO) OR (C15175 =C17998)  or (C15175 = YES and C94631 = NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2012-02011","NCT01711554","A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma","N/A","","","",""
"NCI-2012-02020","NCT01781468","A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) to_x000D_ Reduce Cancer-Related Fatigue in Patients with High Grade Glioma","N/A","","","",""
"NCI-2012-02045","NCT01805076","Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer","N/A","","","",""
"NCI-2012-02057","NCT01730937","Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma","Exclusion","Use of combination anti-retroviral therapy for human immunodeficiency virus (HIV)","HIV = NO or HIV = Y and HAART = NO","(C15175 = NO) OR (C15175 =C17998) or (C15175 = YES and C94631 = NO)","c15175:affirmed;c15175:affirmed;"
"NCI-2012-02067","NCT01349881","A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)","N/A","","","",""
"NCI-2012-02078","NCT01789684","A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics_x000D_ Services Among Breast Cancer Patients","N/A","","","",""
"NCI-2012-02608","NCT01863550","Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)","Inclusion","STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:  * Cluster of differentiation (CD)4 cell count >= 350/mm^3  * No history of acquired immune deficiency syndrome (AIDS)-related illness  * Not currently prescribed zidovudine or stavudine","STEP I: HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=350{cells}/mm3 AND AIDS=NO AND Zidovudine=NO AND Stavudine=NO)","STEP I: C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=350{cells}/mm3 AND C2851=NO AND C947=NO AND C1428=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;c103810:affirmative;c2851:affirmed;c947:affirmed;c1428:affirmed;"
"NCI-2012-02767","NCT01749397","A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers","Exclusion","Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy","(Immunocompromised=NO) OR (HIV=NO) OR (HIV =UNKNOWN) OR (HIV =Y AND  CD4>400 {cells}/mm3 AND HAART=NO)","(C14139=NO) OR (C15175=NO) OR (C15175 =C17998) OR (C15175 =Y AND  C103810>400 {cells}/mm3 AND C94631=NO)","c14139:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c94631:affirmed;"
"NCI-2012-02869","NCT01806129","EROS: Engendering Reproductive Health within Oncologic Survivorship","N/A","","","",""
"NCI-2012-02875","NCT01586403","Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study","Exclusion","Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)","HIV = NO or HIV = Y or HBV = Y or HCV =Y","C15175 = NO OR C15175 =C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;c129452:affirmed;"
"NCI-2012-03124","NCT01755195","A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2012-03125","NCT01767194","A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma","N/A","","","",""
"NCI-2012-03173","NCT01089101","A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma","N/A","","","",""
"NCI-2012-03198","NCT01872975","A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy","N/A","","","",""
"NCI-2013-00046","NCT01771107","A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma","Inclusion","Participants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvement  Participants must discontinue use of the following agents within 7 days prior to therapy  * Strong CYP3A4 inhibitors that treat HIV  * If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy  HIV positive; documentation of HIV-1 infection by means of any one of the following:  * Documentation of HIV diagnosis in the medical record by a licensed health care provider;  * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;  * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;  * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible * NOTE: A â€œlicensedâ€ assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies  Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible ","HIV=YES AND Cytochrome P450 3A4 Inhibitor=NO AND (Erythropoietin=YES OR Erythropoietin=NO) AND (Granulocyte Colony-Stimulating Factor=YES OR Granulocyte Colony-Stimulating Factor=NO)","C15175=YES AND C111373=NO AND (C20429=YES OR C20429=NO) AND (C26078=YES OR C26078=NO)","measurement:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15220:affirmed;c94631:affirmed;measurement:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c20429:affirmed;c26078:affirmed;c20429:affirmed;c26078:affirmed;"
"NCI-2013-00370","NCT01220583","A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol  ","(HIV=NO OR HIV =UNKNOWN) AND AIDS=NO) ","(C15175=NO OR C15175 =C17998) AND C2851=NO) ","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-00426","NCT01824836","A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)","N/A","","","",""
"NCI-2013-00500","NCT01810913","Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients","(HIV =NO) OR (HIV =UNKNOWN) (AIDS=NO) OR (Immunocompromised=NO)   I believe this can be changed to AIDS=NO","C15175 =NO OR C15175 =C17998 AND (C2851=NO AND C14139=NO)  ","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-00595","NCT01817075","Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)","N/A","","","",""
"NCI-2013-00716","NCT00978250","Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)","Exclusion","Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to: active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, ... that would limit compliance with study requirements","(HIV=NO OR HIV =UNKNOWN OR Immunocompromised=NO) AND (Healthy=YES)?","C15175=NO OR C15175 =C17998 OR (C14139=NO AND C115935=YES)","c15220:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-00737","NCT01822496","A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients","(HIV =NO) OR (HIV =UNKNOWN) OR (AIDS=NO) OR (Immunocompromised=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C2851=NO) OR (C14139=NO)","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-00739","NCT01822509","A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation","Exclusion","Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded","(HIV =NO) OR (HIV =UNKNOWN) ","(C15175 =NO) OR (C15175 =C17998) ","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2013-00740","NCT01822522","Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection","Inclusion/Exclusion","Inclusion:  *Participants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration                                                                                                                           *Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests                                                                     * Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accrued                Exclusion:                                                                    Other clinically significant disorders such as:  * Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; ","HIV = Y","C15175 =YES","c15175:affirmed;c15175:possible;c15175:possible;c15175:possible;c15175:possible;c94631:possible;c15175:possible;c94631:possible;c94631:possible;c15175:possible;"
"NCI-2013-00805","NCT01244737","A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children","N/A","","","",""
"NCI-2013-00826","NCT01841723","A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia","Exclusion","Human immunodeficiency virus (HIV)-positive patients will be eligible unless they have been previously diagnosed with an acquired immune deficiency syndrome (AIDS)-defining illness","HIV ","(C15175 =NO) OR (C15175 =C17998) OR (C15175=YES AND C2851=NO)","c15175:affirmed;c15175:affirmed;c2851:affirmed;"
"NCI-2013-00858","NCT01849146","Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-00875","NCT01901094","A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy","N/A","","","",""
"NCI-2013-00877","NCT01851369","A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN)  OR (HIV =YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998)  OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-00890","NCT01935934","A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer","Exclusion","Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-00998","NCT01881867","A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (ProvengeÂ®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Exclusion","Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN) OR (Immunocompromised=NO) OR (HIV =YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C14139=NO) OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01132","NCT01534598","Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors","Exclusion","Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring protease inhibitor therapy, ... that would limit compliance with study requirements","(HIV =NO) OR (HIV =UNKNOWN)  OR (Immunocompromised=NO) OR (HIV =YES AND HIV Protease Inhibitor=NO)","(C15175 =NO) OR (C15175 =C17998)  OR (C14139=NO) OR (C15175 =YES AND C97366=NO)","c15175:affirmed;c15175:affirmed;c97366:affirmed;"
"NCI-2013-01272","NCT01897012","A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas","N/A","","","",""
"NCI-2013-01275","NCT01896999","A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma","Inclusion","PHASE I: Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a cluster of differentiation 4 (CD4) count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded  PHASE II: HIV positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded","(HIV =NO) OR (HIV =UNKNOWN)  OR (HIV =YES AND CD4>400 {cells}/mm3 AND HAART=YES)","(C15175 =NO) OR (C15175 =C17998)  OR (C15175 =YES AND C103810>400 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;c15175:affirmed;"
"NCI-2013-01320","NCT01902173","Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer","Inclusion","Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO AND  CD4>=500 {cells}/mm3)}","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO AND  C103810>=500 {cells}/mm3)}","c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;"
"NCI-2013-01340","NCT01953588","ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study","N/A","","","",""
"NCI-2013-01357","NCT01912625","A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer","Exclusion","Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications  HIV-positive patients on combination antiretroviral therapy are ineligible","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO)","c141405:affirmed;c129452:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01368","NCT01925131","A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)","Inclusion","Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:  * CD4+ cells >= 350/mm^3 (nadir)  * Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART  * No zidovudine or stavudine as part of cART  Patients who are HIV+ and do not meet all of these criteria are not eligible for this study","(HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>=350 {cells}/mm3 AND Viral Load<50 {copies}/mm3 AND HAART=YES) OR (HIV=YES AND CD4>=350 {cells}/mm3 AND Viral Load<25000 {copies}/mm3 AND HAART=NO) AND (Zidovudine=NO) AND (Stavudine=NO)","(C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>=350 {cells}/mm3 AND C92544<50 {copies}/mm3 AND C94631=YES) OR (C15175=YES AND C103810>=350 {cells}/mm3 AND C92544<25000 {copies}/mm3 AND C94631=NO) AND (C947=NO) AND (C1428=NO)","c15175:affirmed;c15175:affirmed;:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c947:affirmed;c1428:affirmed;c15175:affirmed;"
"NCI-2013-01452","NCT00942877","Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01474","NCT01273155","Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction","Exclusion","Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort  * HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4   HIV-positive patients on combination antiretroviral therapy are ineligible","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO AND (Abnormal Liver Function Test=NO OR Abnormal Liver Function Test=YES))","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO AND (C122516=NO OR C122516=YES))                                                         ","c15175:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2013-01475","NCT01273168","Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors","N/A","","","",""
"NCI-2013-01491","NCT01362803","A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","Exclusion","Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation (CD)4 count, not requiring antiretroviral medication will not be excluded","(HIV=NO) OR (HIV =UNKNOWN)  OR (HIV=YES AND  CD4=Sufficient {cells}/mm3 AND HAART=NO)","(C15175=NO) OR (C15175 =C17998)  OR (C15175=YES AND  C103810=C63351 {cells}/mm3 AND C94631=NO)","c141405:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01496","NCT01391962","A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01520","NCT01572493","A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers","Exclusion","Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection","HIV=NO OR HIV =UNKNOWN","C15175=NO OR C15175 =C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2013-01568","NCT01748825","A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors","Exclusion","Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01588","NCT01827384","Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors","Exclusion","TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible  TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2013-01602","NCT01922076","A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas","N/A","","","",""
"NCI-2013-01639","NCT01964300","Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma","N/A","","","",""
"NCI-2013-01702","NCT02004275","A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy","Inclusion","Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:  * No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness  * Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3   * Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3  * Please note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND AIDS=NO AND  AIDS-Related Disorder =NO AND  CD4> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND HAART=NO) OR (HIV=YES AND AIDS=NO AND  AIDS-Related Disorder =NO AND CD4> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND HAART=YES AND Viral Load< 50 {copies}/mm3)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C2851=NO AND  C4991=NO AND  C103810> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND C94631=NO) OR (C15175=YES AND C2851=NO AND  C4991=NO AND C103810> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND C94631=YES AND C92544< 50 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c2851:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;c111373:affirmed;"
"NCI-2013-01703","NCT01940809","A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","(HIV=NO)  OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO)}","(C15175=NO)  OR (C15175 =C17998) OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-01748","NCT01947023","A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible","(HIV=NO) OR HIV=UNKNOWN OR (HIV=Y AND HAART=NO AND  CD4>500 cells/mm3) ","(C15175=NO) OR (C15175=C17998) OR (C15175=YES AND C94631=NO AND  C103810>500 {cells}/mm3)","c15175:affirmed;c15175:affirmed;"
"NCI-2013-01760","NCT01988571","Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)","N/A","","","",""
"NCI-2013-01850","NCT01993810","Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC","Exclusion","Severe, active co-morbidity, defined as follows:  * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol","(HIV=NO OR HIV =UNKNOWN) AND AIDS=NO","(C15175=NO OR C15175 =C17998) AND C2851=NO","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-01904","NCT02054741","A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults","N/A","","","",""
"NCI-2013-01999","NCT01946789","A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients","(HIV=NO OR HIV =UNKNOWN) ","(C15175=NO OR C15175 =C17998) ","c15175:affirmed;c15175:affirmed;"
"NCI-2013-02103","NCT01989585","Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV =UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175 =C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2013-02167","NCT01979536","A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)","Exclusion","Patients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later date","(HIV=NO OR HIV =UNKNOWN) ","(C15175=NO OR C15175 =C17998) ","c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2013-02229","NCT02003222","A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults","Inclusion","Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:  * No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low  * Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia  * Patient must have serum HIV viral load of < 200 copies/mm^3  * Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy  * Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or zidovudine.  * It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine","(HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND AIDS-Related Disorder =NO AND Healthy=YES AND Viral Load>=200 {copies}/mm3 AND HAART=YES AND HIV Protease Inhibitor=NO AND Cobicistat=NO AND  Stavudine=NO AND Zidovudine=NO)","(C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C4991=NO AND C115935=YES AND C92544>=200 {copies}/mm3 AND C94631=YES AND C97366=NO AND C97360=NO AND  C1428=NO AND C947=NO)","c15175:affirmed;c15175:affirmed;c2851:possible;:possible;c94631:possible;:possible;c115935:possible;c15175:possible;c15175:possible;c92544:possible;measurement:possible;c94631:possible;c97366:possible;c97360:possible;c1428:possible;c947:possible;"
"NCI-2013-02238","NCT01896869","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer","Exclusion","Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded","(HIV=NO) OR (HIV =UNKNOWN)","(C15175=NO) OR (C15175 =C17998)","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2013-02284","NCT02065687","A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer","N/A","","","",""
"NCI-2013-02288","NCT02059499","A Randomized, Phase III Study of Intra-anal Imiquimod 2.5 % vs. Topical 5-Fluorouracil 5% vs. Observation for the Treatment of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Positive Men and Women","Exclusion/Inlusion","EXCLUSION  Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair  Inclusion:  HIV-positive; documentation of HIV-1 infection by means of any one of the following:   * Documentation of HIV diagnosis in the medical record by a licensed health care provider  * Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participantâ€™s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participantâ€™s name)  * HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL  * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay  Cluster of differentiation (CD)4 count >= 200 within 120 days prior to enrollment or plasma HIV-1 RNA < 200 copies/mL within 120 days prior to randomization ","HIV=YES AND  (CD4>=200 {cells}/mm3 OR Viral Load<200 {copies}/mm3)","C15175=YES AND (C103810>=200 {cells}/mm3 OR C92544<200 {copies}/mm3)","c94631:negated;c15175:negated;c15175:negated;c15220:negated;c94631:negated;measurement:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;"
"NCI-2013-02426","NCT02029950","A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin, and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS","Inclusion","Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy are eligible for inclusion; the use of zidovudine is not allowed","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Zidovudine=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C947=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;c947:affirmed;"
"NCI-2014-00115","NCT02015104","A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVACâ„¢ versus BCG Given Alone in Adults with High Grade Non-muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG","Exclusion","Patients unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczematoid skin disorders, or (d) immunocompromised individuals, such as those with human immunodeficiency virus (HIV)","(HIV=NO OR HIV=UNKNOWN) AND (Immunocompromised=NO)","(C15175=NO OR C15175=C17998) AND (C14139=NO)","measurement:affirmed;c14139:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-00416","NCT02070549","A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction","Exclusion","Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)  HIV-positive patients on combination antiretroviral therapy are ineligible","HIV =NO OR OR HIV=UNKNOWN OR (HIV =Y AND HAART=NO AND CD4>=500 cells/mm3)","C15175 =NO OR  C15175=C17998 OR (C15175 =YES AND C94631=NO AND  C103810>=500 cells/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-00461","NCT02079740","An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects with KRAS or NRAS Mutation-Positive Advanced Solid Tumors","Exclusion","Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications","HIV=NO OR HIV=UNKNOWN OR (HIV =YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=NO)","c141405:affirmed;c129452:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-00547","NCT02095132","A Phase 1/2 Study of AZD1775 (MK-1775) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors","N/A","","","",""
"NCI-2014-00615","NCT02097225","Phase I Study of AT13387 in Combination with Dabrafenib and Trametinib in Patients with BRAF-Mutant Melanoma and Other Solid Tumors","Exclusion","Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV =YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-00616","NCT02152982","A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation","N/A","","","",""
"NCI-2014-00620","NCT02101775","A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV =YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-00623","NCT02143726","Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","N/A","","","",""
"NCI-2014-00627","NCT02154490","A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)","Inclusion","Patients with a known history of human immunodeficiency virus (HIV) seropositivity:  * Must have undetectable viral load using standard HIV assays in clinical practice  * Must have cluster of differentiation (CD)4 count >= 400/mcL  * Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)  * Must not be newly diagnosed within 12 months prior to sub-study registration","HIV=NO OR HIV=UNKNOWN OR (HIV =YES AND VIRAL LOAD=0 {copies}/mm3 AND CD4>=400 {cells}/mm3 AND Prevention and Treatment of Opportunistic Infection =NO AND Diagnosis>12 months)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C92544=C111568 {copies}/mm3 AND C103810>=400 {cells}/mm3 AND C15840=NO AND C15220>12 mo)","c15175:affirmed;c15175:affirmed;c111568:affirmed;c92544:affirmed;c15175:affirmed;c3289:affirmed;"
"NCI-2014-00629","NCT02101788","A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer","Exclusion","patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications","HIV=NO OR HIV=UNKNOWN OR (HIV =Yes AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175 =Yes AND C94631=NO)","c15175:affirmed;c15175:affirmed;"
"NCI-2014-00631","NCT02101853","Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)","Exclusion","Patients with known human immunodeficiency virus (HIV) infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2014-00634","NCT02101905","Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors are ineligible","HIV=NO OR HIV=UNKNOWN OR ((HIV =YES AND (Cytochrome P450 3A4 Inhibitor=NO OR  Cytochrome P450 3A4 Inducer =NO))","C15175=NO OR C15175=C17998 OR ((C15175 =YES AND (C111373=NO OR  C111374=NO))","c15175:affirmed;c15175:affirmed;c111374:affirmed;"
"NCI-2014-00635","NCT02135042","Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)","Exclusion","Severe, active co-morbidity, defined as follows:  * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol","HIV=NO OR HIV=UNKNOWN OR AIDS=NO","C15175=NO OR C15175=C17998 OR C2851=NO","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-00636","NCT02135419","ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study","Inclusion","HIV positive; documentation of HIV-1 infection by means of any one of the following:  * Documentation of HIV diagnosis in the medical record by a licensed health care provider;  * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participantâ€™s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participantâ€™s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);  * HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;  * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay  * NOTE: A â€œlicensedâ€ assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies","HIV =YES","C15175 =YES","c15175:affirmed;c15175:affirmed;c15220:affirmed;c94631:affirmed;measurement:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-00640","NCT02255461","Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors","N/A","","","",""
"NCI-2014-00643","NCT02101944","Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma","Inclusion","Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2014-00644","NCT02032823","A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy","Exclusion","Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:  * Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3  * History of acquired immune deficiency syndrome (AIDS) indicator conditions  * Anti-retroviral therapy with any potent CYP3A4 inhibitor","HIV=NO OR HIV=UNKNOWN OR (HIV =YES AND CD4>=250 {cells}/mm3 AND AIDS=NO AND Cytochrome P450 3A4 Inhibitor=NO)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C103810>=250 {cells}/mm3 AND C2851=NO AND C111373=NO)","c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;c2851:affirmed;"
"NCI-2014-00677","NCT02176967","Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-high-risk Neuroblastoma","N/A","","","",""
"NCI-2014-00686","NCT02152137","A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer","Inclusion","Although they will not be considered formal eligibility (exclusion) criteria, physicians should recognize that the following may seriously increase the risk to the patient entering this protocol:  * Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient  ","N/A","IGNORE?","c15175:affirmed;c15175:affirmed;"
"NCI-2014-00688","NCT02379416","Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV =NO OR HIV =UNKNOWN OR (HIV =YES AND HAART=NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-00702","NCT02206334","A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases","Exclusion","Severe, active co-morbidity, defined as follows:   * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) 4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol  ","HIV =NO OR HIV =UNKNOWN OR (HIV =YES AND CD4>=200 {cells}/mm3) AND HAART=YES)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>=200 {cells}/mm3) AND C94631=YES)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2014-00712","NCT02112916","A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)","N/A","","","",""
"NCI-2014-00746","NCT02115282","A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer","Inclusion","Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3","HIV =NO OR HIV =UNKNOWN OR (HIV =YES AND CD4>250 {cells}/mm3)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>250 {cells}/mm3)","c15175:affirmed;c15175:affirmed;"
"NCI-2014-00804","NCT02116777","A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies","N/A","","","",""
"NCI-2014-00816","NCT02211755","Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV =NO OR HIV =UNKNOWN OR (HIV =YES AND HAART=NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-00849","NCT02200042","Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma","Exclusion","Severe, active co-morbidity, defined as follows:   * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol  ","HIV=NO OR HIV=Unknown OR (HIV=YES AND  CD4>=200 {cells}/mm3) AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=200 {cells}/mm3) AND C94631=YES)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2014-00850","NCT02177695","A Randomized Phase II Study of Co-expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer","N/A","","","",""
"NCI-2014-00852","NCT02190279","A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer","N/A","","","",""
"NCI-2014-00907","NCT02133183","Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-01028","NCT02249949","A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma","N/A","","","",""
"NCI-2014-01043","NCT02143401","A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-01047","NCT02143414","A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Postive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL with Known or Presumed Activating Dastinib-Sensitive Mutations or Kinase Fusions (DSMKF)","Inclusion","Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:  * No history of acquired immune deficiency syndrome (AIDS)-defining conditions  * CD4 cells > 350 cells/mm^3  * If on antiretroviral agents, must not include zidovudine or stavudine  * Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART  * Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactions","HIV=NO OR HIV=Unknown OR (HIV=YES AND AIDS=NO AND  CD4> 350 {cells}/mm3 AND HAART=NO AND Viral Load<=25000 {copies}/mm3) OR (HIV=YES AND AIDS=NO AND CD4> 350 {cells/mm3 AND HAART=YES AND Zidovudine=NO AND Stavudine= NO AND Viral Load<=50 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C2851=NO AND  C103810> 350 {cells}/mm3 AND C94631=NO AND C92544<=25000 {copies}/mm3) OR (C15175=YES AND C2851=NO AND C103810> 350 {cells/mm3 AND C94631=YES AND C947=NO AND C1428= NO AND C92544<=50 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c2851:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;c94631:affirmed;c947:affirmed;c1428:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c94631:affirmed;c63350:affirmed;"
"NCI-2014-01072","NCT02179086","Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma","Exclusion","Severe, active co-morbidity, defined as follows:   * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol  ","(HIV=NO OR HIV=Unknown) AND AIDS=NO","(C15175=NO OR C15175=C17998) AND C2851=NO","c2851:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-01106","NCT02152995","A Phase 2 Study of Trametinib in Combination with Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers","Exclusion","Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications  HIV-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c141405:affirmed;c129452:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-01107","NCT02159989","Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers","Exclusion","Patients with human immunodeficiency virus (HIV) will not be denied an opportunity to participate in this clinical trial, if they have adequate cluster of differentiation (CD)4 counts (> 250 CD4+ T lymphocytes/uL) and would be able to be maintained on an antiretroviral combination without pronounced effects on cytochrome (CYP)3A4, 2C9, or 2C19","{(HIV=NO) OR (HIV=Y AND HAART=NO AND  CD4>250 cells/mm3) AND (HIV=Y AND HAART=Y AND  CD4>250 cells/mm3)}","{(C15175=NO) OR (C15175=Y AND C94631=NO AND  C103810>250 cells/mm3) AND (C15175=Y AND C94631=Y AND  C103810>250 cells/mm3)}","c15175:affirmed;c15175:affirmed;measurement:affirmed;:affirmed;c94631:affirmed;"
"NCI-2014-01118","NCT02142803","A Phase 1 Study of MLN0128 and Bevacizumab in Patients with Recurrent Glioblastoma and Other Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO) OR (HIV=YES AND HAART=YES AND  CD4>C25555 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO) OR (C15175=YES AND C94631=YES AND  C103810>C25555 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;:affirmed;c94631:affirmed;"
"NCI-2014-01222","NCT02304458","A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab","Exclusion","Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2014-01223","NCT02166463","A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults","Exclusion","Patients known to be positive for human immunodeficiency virus (HIV) are not eligible","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2014-01340","NCT02180867","Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754)","Exclusion","Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible","(HIV=NO) OR (HIV=Y AND HAART=NO)","(C15175=NO) OR (C15175=Y AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-01470","NCT02196181","A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma","Inclusion","Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:  * Cluster of differentiation (CD)4 cells >= 500/uL  * Serum HIV viral load of < 25,000 IU/ml  * No current antiretroviral therapy  ** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)","HIV=NO OR HIV=Unknown OR (HIV=YES AND  CD4>=500 {cells}/mm3 AND Viral Load<25000 {copies}/mm3 AND HAART=NO)                                          ","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=500 {cells}/mm3 AND C92544<25000 {copies}/mm3 AND C94631=NO)                                          ","c15175:affirmed;c15175:affirmed;c15175:affirmed;c92544:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2014-01497","NCT02270450","Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction","N/A","","","",""
"NCI-2014-01507","NCT02201992","A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein","N/A","","","",""
"NCI-2014-01508","NCT02193282","Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)","N/A","","","",""
"NCI-2014-01696","NCT02375204","A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors","Inclusion","Negative serology (antibody test) for the following infectious diseases:  * Human immunodeficiency virus (HIV) type 1 and 2  * Human T-cell leukemia virus (HTLV) type 1 and 2 (mandatory in United States [US] but optional in Canada and Europe)  * Hepatitis B surface antigen  * Hepatitis C antibody","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2014-01747","NCT02224781","A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma","Inclusion","Individuals who are known to be human immunodeficiency virus (HIV) infected are eligible (note: HIV testing is not required for entry into the study)","HIV=NO OR HIV=Unknown OR HIV=YES","C15175=NO OR C15175=C17998 OR C15175=YES","c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-01754","NCT02203526","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma","Exclusion","Human immunodeficiency virus (HIV) positive patients will be excluded with the exception of patients without CD4 depletion (i.e. above the institutional lower limit of normal) and who have no other acquired immune deficiency syndrome (AIDS)-related complications and who have Epstein-Barr virus (EBV) negative tumors; the number of patients in this category is expected to be very low and the principal investigator (PI) will decide their eligibility on a case by case basis","HIV=NO OR HIV=Unknown OR (HIV=YES AND  CD4>C25555 {cells}/mm3 AND AIDS-Related Disorder =NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>C25555 {cells}/mm3 AND C4991=NO)","c15175:affirmed;c15175:affirmed;:affirmed;c25555:affirmed;c2851:affirmed;"
"NCI-2014-01810","NCT02364557","A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer","Exclusion","Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=YES AND  CD4>=200 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND  C103810>=200 {cells}/mm3)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2014-01820","NCT02445391","A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy","N/A","","","",""
"NCI-2014-01927","NCT02243605","A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients with Relapsed Osteosarcomas and Ewing Sarcomas","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-01984","NCT02298959","A Phase 1 Trial of MK-3475 plus Ziv-Aflibercept in Patients with Advanced Solid Tumors","Exclusion","Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:  * They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective  * They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL  * They must not be receiving prophylactic therapy for an opportunistic infection","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=YES AND Healthy=YES AND CD4> 250 {cells}/mm3 AND Prevention and Treatment of Opportunistic Infection =NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C115935=YES AND C103810> 250 {cells}/mm3 AND C15840=NO)","c15175:affirmed;c15175:affirmed;c115935:affirmed;c15175:affirmed;c3289:affirmed;"
"NCI-2014-02020","NCT02575794","Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-02056","NCT02437851","A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons","Exclusion/Inclusion","EXCLUSION: Patients who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable  Patients who are receiving any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents or investigational agents within 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational agents for hepatitis C  INCLUSION: HIV positive; HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participantâ€™s HIV status based on either: 1) approved diagnostic tests or 2) the referring physicianâ€™s written record that HIV infected was documented, with supporting information on the subjectâ€™s relevant medical history and/or current management of HIV infection","HIV=YES","C15175=YES","c94631:affirmed;c15175:affirmed;c63350:affirmed;c94631:affirmed;c15175:affirmed;c129452:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-02167","NCT02275533","Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)","Exclusion","Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by PCR is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul","HIV=NO OR HIV=Unknown OR (HIV=YES AND (AIDS=YES OR AIDS=NO) AND (Viral Load=0 {copies}/mm3 AND (HAART=YES OR HAART=NO) AND  CD4>=350 {cells}/mm3))","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C2851=YES OR C2851=NO) AND (C92544=C111568 {copies}/mm3 AND (C94631=YES OR C94631=NO) AND  C103810>=350 {cells}/mm3))","c15175:affirmed;c15175:affirmed;c2851:affirmed;c92544:affirmed;c111568:affirmed;"
"NCI-2014-02197","NCT02281760","A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-02266","NCT02339740","A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid","N/A","","","",""
"NCI-2014-02267","NCT02412670","A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma","Inclusion","Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-02379","NCT02496208","A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectable","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=YES AND  CD4>350 {cells}/mm3 AND Viral Load=0 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND  C103810>350 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c92544:affirmed;c111568:affirmed;"
"NCI-2014-02380","NCT02306161","Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma","N/A","","","",""
"NCI-2014-02403","NCT02428192","A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus","Exclusion","Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) ","(HIV=NO OR HIV=Unknown) AND (AIDS=NO OR AIDS=Unknown)","(C15175=NO OR C15175=C17998) AND (C2851=NO OR C2851=C17998)","c15175:possible;c15175:possible;c2851:possible;"
"NCI-2014-02405","NCT02438722","A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)","Inclusion","Patients must not have a known history of human immunodeficiency virus (HIV) seropositive","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2014-02410","NCT02323880","A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors","N/A","","","",""
"NCI-2014-02413","NCT02063828","Reducing Lung Cancer Survivors' Anxiety (RELAX)","N/A","","","",""
"NCI-2014-02424","NCT02498600","Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Exclusion","In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)","HIV=NO OR HIV=Unknown OR (HIV=YES AND (AIDS=YES OR AIDS=NO OR AIDS=Unknown) AND HAART=YES AND CD4>350 {cells}/mm3 AND Viral Load=0 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C2851=YES OR C2851=NO OR C2851=C17998) AND C94631=YES AND C103810>350 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c2851:affirmed;c94631:affirmed;c92544:affirmed;"
"NCI-2014-02474","NCT02317874","A Phase 1 Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV =YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2014-02559","NCT01885455","Improving Resection Rates Among African Americans with NSCLC (""Southern Lung Cancer Study"")","N/A","","","",""
"NCI-2014-02672","NCT02337517","Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) with GDC-0449 (GDC-0449)","Inclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria:   * Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition  * Cluster of differentiation (CD)4 cell count >= 250  * Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone  * Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449","HIV=NO OR HIV=Unknown OR (HIV =YES AND HAART=YES AND AIDS=NO AND CD4>=250 {cells}/mm3 AND Treatment-sensitive HIV=YES AND Healthy=YES)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=YES AND C2851=NO AND C103810>=250 {cells}/mm3 AND Treatment-sensitive HIV =YES AND C115935=YES)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c2851:affirmed;c2851:affirmed;:affirmed;c103810:affirmative;measurement:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2014-02674","NCT02339571","Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma","Inclusion","Patients with human immunodeficiency virus (HIV) infection are ineligible","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-00030","NCT02360215","A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases","Exclusion","Severe, active co-morbidity defined as follows:  * Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=Unknown OR (HIV =YES AND CD4>=200 {cells}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C103810>=200 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2015-00052","NCT02799485","A Phase II Study of sEphB4-HSA in Kaposi Sarcoma","Exclusion/Inclusion","EXCLUSION: Participants who refuse antiretroviral therapy for HIV, if HIV positive  INCLUSION:  Documentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection  * If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subjectâ€™s HIV status  If participant is HIV positive, participants must be on a stable antiretroviral regimen for at least 12 weeks prior to study enrollment","HIV=NO OR HIV=Unknown OR (HIV =YES AND HAART=YES AND HAART>12 weeks)","C15175=NO OR C15175=C17998 OR (C15175 =YES AND C94631=YES AND C94631>12 wk)","c94631:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-00054","NCT02465060","Molecular Analysis for Therapy Choice (MATCH)","Inclusion","Patients who are human immunodeficiency virus (HIV)-positive are eligible if:   * CD4+ cell count greater or equal to 250 cells/mm^3  * If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used  * No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts  * Probable long-term survival with HIV if cancer were not present","HIV =NO OR HIV =Unknown OR (HIV =YES AND  CD4 {cells}/mm3 AND ((HAART=NO) OR (HAART=YES AND HIV Protease Inhibitor=NO)) AND AIDS=NO AND Healthy=YES","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND  C103810 {cells}/mm3 AND ((C94631=NO) OR (C94631=YES AND C97366=NO)) AND C2851=NO AND C115935=YES","c15175:affirmed;c15175:affirmed;:affirmed;:affirmed;c103810:affirmative;measurement:affirmed;measurement:affirmed;c94631:affirmed;c94631:affirmed;c97366:affirmed;c97366:affirmed;c2851:affirmed;:affirmed;:affirmed;c103810:affirmative;c15175:affirmed;"
"NCI-2015-00121","NCT03047213","An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patientâ€™s general health and cluster of differentiation (CD)4 counts are within acceptable levels","HIV =NO OR HIV =Unknown OR (HIV =YES AND ((HAART=NO) OR (HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO AND CD4=AC63350 {cells}/mm3)))","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND ((C94631=NO) OR (C94631=YES AND C111373=NO AND C103810=AC63350 {cells}/mm3)))","c15175:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;c111374:affirmed;c63350:affirmed;"
"NCI-2015-00127","NCT02535312","Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV =NO OR HIV =Unknown OR (HIV =YES AND HAART=NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-00128","NCT02488967","A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer","Exclusion","Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions","{(HIV =NO) OR (HIV =Y AND CD4>=250 cells/mm3 AND AIDS=NO)}","(C15175 =NO) OR (C15175 =Y AND C103810>=250 {cells/mm3} AND C2851=NO)","c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;c2851:affirmed;"
"NCI-2015-00130","NCT02359565","A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors","Exclusion","EXCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C):  HIV-positive patients are eligible if the following criteria are met:  * Stable on their antiretroviral agents  * Have CD4 counts above 400  * Undetectable viral loads, and  * No need for prophylactic medications for an opportunistic infections   EXCLUSION CRITERIA FOR DIPG (STRATUM A):  human immunodeficiency virus (HIV)-positive patients are eligible if the following criteria are met:  * Stable on their antiretroviral agents  * Have CD4 counts above 400  * Undetectable viral loads, and  * No need for prophylactic medications for an opportunistic infections  EXCLUSION CRITERIA FOR NB-NGG (STRATUM B): HIV-positive patients are eligible if the following criteria are met:  * Stable on their antiretroviral agents  * Have CD4 counts above 400  * Undetectable viral loads, and  * No need for prophylactic medications for an opportunistic infections","HIV =NO OR HIV =Unknown OR (HIV =YES AND HAART=YES AND CD4>400 {cells}/mm3 AND Viral Load=0 {copies}/mm3 AND Prevention and Treatment of Opportunistic Infection =NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C94631=YES AND C103810>400 {cells}/mm3 AND C92544=0 {copies}/mm3 AND C15840=NO)","c94631:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c92544:affirmed;c3289:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c92544:affirmed;c3289:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c92544:affirmed;c3289:affirmed;"
"NCI-2015-00159","NCT02363283","A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200","HIV =NO OR HIV =Unknown OR (HIV =YES AND CD4>=200 {cells}/mm3)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>=200 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;"
"NCI-2015-00257","NCT02381548","A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia","Inclusion","Human immunodeficiency virus (HIV)-infected persons are eligible if they meet other eligibility criteria including the following:  * No prior acquired immune deficiency syndrome (AIDS)-defining condition other than cluster of differentiation (CD)4+ cells nadir < 200/mm^3  * Pre-leukemia CD4+ cell count >= 250/mm^3  * Willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study; no zidovudine- and no ritonavir-containing regimens and no 3-drugs-in-1 pill regimens containing pharmacologic boosters are allowed; recommended regimens are integrase inhibitors combined with tenofovir and emtricitabine","HIV =NO OR HIV =Unknown OR (HIV =YES AND AIDS=NO AND CD4>=200 {cells}/mm3 AND HAART=YES AND Zidovudine=NO AND Ritonavir=NO AND 3-drugs-in-1 pill=NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C2851=NO AND C103810>=200 {cells}/mm3 AND C94631=YES AND C947=NO AND C1609=NO AND 3-drugs-in-1 pill=NO)","c15175:affirmed;c15175:affirmed;c2851:affirmed;:affirmed;:affirmed;c103810:affirmative;c94631:affirmed;c947:affirmed;no:affirmed;c:affirmative;"
"NCI-2015-00258","NCT02381561","Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers","Inclusion","Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy","HIV =NO OR HIV =Unknown OR (HIV =YES AND CD4>=250 {cells}/mm3 AND HAART=YES)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>=250 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;"
"NCI-2015-00260","NCT02500797","Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma","Inclusion","No history of the following:  * Patients with human immunodeficiency virus (HIV) are eligible if the lymphocytes > 350 cluster of differentiation (CD)4+ cells and no detectable viral load  ","HIV =NO OR HIV =Unknown OR (HIV =YES AND CD4>350 {cells}/mm3 AND Viral Load=0 {copies}/mm3)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>350 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;measurement:possible;c92544:possible;"
"NCI-2015-00323","NCT02516423","Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy","Inclusion","Human immunodeficiency (HIV) positive (+) patients are eligible provided they meet the other eligibility criteria and:  * Cluster of differentiation (CD)4+ cells are >= 250/mm^3  * There is no history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ cell count  * The following antiretroviral agents are not allowed: zidovudine, stavudine, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, combination pills with pharmacologic boosters  * Recommended antiretroviral regimens to avoid pharmacokinetic (PK) interactions include strand integrase inhibitors with nucleoside reverse transcriptase inhibitors (for example, dolutegravir given with tenofovir and emtricitabine)","HIV =NO OR HIV =Unknown OR (HIV =YES AND CD4>=250 {cells}/mm3 AND AIDS=NO AND Zidovudine=NO AND Stavudine=NO AND HIV Protease Inhibitor=NO AND Non-nucleoside Reverse-transcriptase Inhibitors=NO AND Combination pills with pharmacologic boosters=NO)","C15175 =NO OR C15175 =C17998 OR (C15175 =YES AND C103810>=250 {cells}/mm3 AND C2851=NO AND C947=NO AND C1428=NO AND C97366=NO AND C97453=NO AND Combination pills with pharmacologic boosters=NO)","c15175:affirmed;c2851:affirmed;:affirmed;:affirmed;c103810:affirmative;c94631:affirmed;c947:affirmed;c1428:affirmed;c97366:affirmed;c97453:affirmed;no:affirmed;c:affirmative;code:affirmative;c94631:affirmed;"
"NCI-2015-00324","NCT02521493","Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome","N/A","","","",""
"NCI-2015-00328","NCT02392429","Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging","N/A","","","",""
"NCI-2015-00378","NCT02659800","The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide","Exclusion","Patients with human immunodeficiency virus (HIV) are excluded","HIV =NO OR HIV =Unknown","C15175 =NO OR C15175 =C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-00383","NCT02398773","[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer","N/A","","","",""
"NCI-2015-00456","NCT02407405","Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","Exclusion","Uncontrolled intercurrent illness including, but not limited to: human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements; patients with HIV who have adequate CD4 counts and who have no requirement for antiviral therapy will be eligible","HIV =NO OR HIV =Unknown OR (HIV=YES AND CD4=Sufficient {cells}/mm3 AND HAART=NO)","C15175 =NO OR C15175 =C17998 OR (C15175=YES AND C103810=C63351 {cells}/mm3 AND C94631=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;"
"NCI-2015-00461","NCT02408861","A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma","Inclusion","HIV plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays (limit of detection: 75) within 4 weeks prior to registration  HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participantâ€™s relevant medical history and/or current management of HIV infection  Participants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable KS despite HAART for greater than or equal to 3 months)  * For participants in the relapsed refractory HIV-cHL expansion cohort, participants must have histologically confirmed, relapsed/refractory (defined as relapsed/refractory to one or greater lines of therapy) HIV-associated classical Hodgkin lymphoma  Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment  Criteria for Solid Tumor Expansion and Lymphoma Cohorts:  for the relapsed refractory HIV-cHL cohort, participants with CD4 count >= 100/mm^3 are permitted","HIV =YES AND Viral Load=0 {copies}/mm3 AND HAART=YES","C15175 =YES AND C92544=C111568 {copies}/mm3 AND C94631=YES","c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;:affirmed;"
"NCI-2015-00537","NCT02588443","Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine for Patients with Newly Diagnosed Resectable Pancreatic Carcinoma","N/A","","","",""
"NCI-2015-00543","NCT02470091","Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma","N/A","","","",""
"NCI-2015-00545","NCT02417701","A Phase 2 Study of MLN0128 (TAK-228) in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations","N/A","","","",""
"NCI-2015-00546","NCT02523014","Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations","N/A","","","",""
"NCI-2015-00547","NCT02595424","Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas","Inclusion","Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible","(HIV=NO OR HIV=Unknown) AND HAART=NO","(C15175=NO OR C15175=C17998) AND C94631=NO","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-00606","NCT02446600","A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Exclusion","Known human immunodeficiency virus (HIV)-positive individuals are ineligible","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-00651","NCT02502266","A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)","Exclusion","Known human immunodeficiency virus (HIV)-positive individuals are ineligible","HIV=NO OR HIV=Unknown","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-00668","NCT02443077","A Randomized Double-Blind Phase III Study of Ibrutinib during and following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype","Inclusion","Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:  * There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma  * In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma  * Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed  * Zidovudine is not allowed  * Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed  * Patients with multi-drug resistant HIV are not eligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND AIDS=NO AND Healthy=YES AND HIV Protease Inhibitor=NO AND Zidovudine=NO AND Treatment-sensitive HIV=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C2851=NO AND C115935=YES AND C97366=NO AND C947=NO AND Treatment-sensitive HIV=YES)","c15175:affirmed;c15175:affirmed;c2851:affirmed;:affirmed;c15175:affirmed;c15220:affirmed;c15175:affirmed;c97366:affirmed;c15175:affirmed;c97360:affirmed;c15175:affirmed;"
"NCI-2015-00695","NCT02423057","Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients with Advanced Solid Tumors","Exclusion","Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to known human immunodeficiency virus (HIV) infection requiring protease inhibitor therapy, ","HIV=NO OR HIV=Unknown OR (HIV=YES AND (HAART=YES OR HAART=NO) AND HIV Protease Inhibitor=NO)","C15175=NO OR C15175=C17998 OR (HIV=YES AND (C94631=YES OR C94631=NO) AND C97366=NO)","c15175:negated;c15175:negated;c97366:affirmed;"
"NCI-2015-00741","NCT02453620","A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors","Exclusion","Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; ","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)}","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)}","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-00744","NCT02564198","A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors","Exclusion","Immunocompromised patients (other than that related to the primary oncologic diagnosis or to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive are not eligible","(HIV=NO OR HIV=Unknown) AND Immunocompromised=NO  ","(C15175=NO OR C15175=C17998) AND C14139=NO  ","c14139:affirmed;c15220:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2015-00835","NCT02466971","A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer","Inclusion","Patient does not have known human immunodeficiency virus syndrome (HIV, testing optional); known HIV-positive patients receiving combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO AND AIDS=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO AND C2851=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-00866","NCT02474173","Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer","Exclusion","Patients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the study","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01000","NCT02484430","A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)","Inclusion","Human immunodeficiency virus (HIV) infected patients (if HIV positive)  * HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:  ** No history of acquired immune deficiency syndrome (AIDS) defining illness other than an historic CD4+ T-cell nadir < 200/mm^3  ** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:  *** The CD4+ T-cell counts were generally in excess of 300/mm^3  *** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy  *** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms  *** Zidovudine is not allowed as part of the anti-HIV therapy","HIV=NO OR HIV=Unknown OR {HIV=YES AND AIDS=NO AND  CD4>=200 {cells}/mm3 AND (HAART=NO OR (HAART=YES AND Viral Load<200 {copies}/mm3)) AND Zidovudine=NO) AND CD4>=300","C15175=NO OR C15175=C17998 OR {C15175=YES AND C2851=NO AND  C103810>=200 {cells}/mm3 AND (C94631=NO OR (C94631=YES AND C92544<200 {copies}/mm3)) AND C947=NO) AND  C103810>=300 {cells/mm3}","c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c2851:affirmed;:affirmed;c15220:affirmed;c15175:affirmed;:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;c2851:affirmed;c947:affirmed;"
"NCI-2015-01001","NCT02484443","A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma","N/A","","","",""
"NCI-2015-01053","NCT02496663","A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01097","NCT02498613","A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01098","NCT02503709","A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=Unknown OR (HIV=YES AND (HAART=NO OR (HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO AND Cytochrome P450 3A4 Inducer =NO) AND CD4>=200 {cells}/mm3))","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C94631=NO OR (C94631=YES AND C111373=NO AND C111374=NO) AND C103810>=200 {cells}/mm3))","c15175:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c94631:affirmed;"
"NCI-2015-01139","NCT02503722","A Phase 1 Trial of MLN0128 in Combination with AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) after Progression on a Previous EGFR Tyrosine Kinase Inhibitor","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MLN0128 and AZD9291;  in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2015-01144","NCT02613364","A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors","N/A","","","",""
"NCI-2015-01178","NCT02308085","A Study Evaluating the Pregnancy Outcomes and Safety of_x000D_ Interrupting Endocrine Therapy for Young Women with_x000D_ Endocrine Responsive Breast Cancer Who Desire Pregnancy","N/A","","","",""
"NCI-2015-01236","NCT02562716","A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma","N/A","","","",""
"NCI-2015-01270","NCT02520778","A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor","Exclusion","Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01271","NCT02520791","A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)","Exclusion","History of human immunodeficiency virus (HIV) infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-01348","NCT02490878","Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases","N/A","","","",""
"NCI-2015-01408","NCT02535325","A Phase I Study of Methoxyamine Combined with Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer","Exclusion","Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c94631:affirmed;"
"NCI-2015-01411","NCT02535338","A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01548","NCT02635009","Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer","Exclusion","Severe, active comorbidity, defined as follows:  * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter  ** Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to Step 1 registration  ** Note: HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND CD4>=200 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C103810>=200 {cells}/mm3)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2015-01640","NCT02568553","A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)","Inclusion","Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following:   * No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)  * After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible  * At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3  * At the time of study entry the HIV viral load must be undetectable by standard laboratory assay   * During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status  * No history of non-adherence to cART and willing to adhere to cART while on study  * Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:  ** Efavirenz not allowed due to potential central nervous system (CNS) toxicity  ** Stavudine not allowed due to potential neuropathic effects  ** Zidovudine not allowed due to myelosuppressive effects  * Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND AIDS=NO AND cART=YES AND CD4>=250 {cells}/mm3 AND Viral Load=0 {copies}/mm3 AND AIDS-Related Disorder =NO AND Efavirenz=NO) VERY COMPLICATED (I KEPT IT AT >=250 TO INCLUDE MORE FOR MATCH, CLINICIAN CAN EXCLUDE AFTERWARDS)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C2851=NO AND C94631=YES AND C103810>=250 {cells}/mm3 AND C92544=C111568 {copies}/mm3 AND  C4991=NO AND C29027=NO)","c15175:affirmed;c15175:affirmed;c2851:affirmed;:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c15220:affirmed;:affirmed;c15220:affirmed;measurement:affirmed;:affirmed;c15175:affirmed;c92544:affirmed;c111568:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2015-01642","NCT02567409","A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma","N/A","","","",""
"NCI-2015-01643","NCT02567422","A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)","Exclusion","Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4=Sufficient AND Viral Load=Acceptable AND HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO AND Cytochrome P450 3A4 Inducer=NO) ","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810=C63351 AND C92544=C63350 AND C94631=YES AND C111373=NO AND C111374=NO) ","c15175:affirmed;c15175:affirmed;:affirmed;c92544:affirmed;c94631:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2015-01644","NCT02567435","A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)","N/A","","","",""
"NCI-2015-01681","NCT02572453","Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL","Inclusion","Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:  * CD4+ T-cells >= 250/mm^3  * HIV sensitive to antiretroviral therapy  * Zidovudine not allowed  * Long term survival anticipated on the basis of HIV alone were it not for the lymphoma  * No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=250 {cells}/mm3 AND Treatment-sensitive HIV=YES AND Zidovudine=NO AND HEALTHY=YES AND AIDS=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=250 {cells}/mm3 AND Treatment-sensitive HIV=YES AND C947=NO AND C115935=YES AND C2851=NO)","c15175:affirmed;c15175:affirmed;:affirmed;c15175:affirmed;c94631:affirmed;c15175:affirmed;c2851:affirmed;"
"NCI-2015-01706","NCT02749903","A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers","N/A","","","",""
"NCI-2015-01707","NCT02761057","A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)","Inclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01744","NCT02581930","A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patientâ€™s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND CD4>Lower Limit of Normal {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C103810>C25555 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c25555:affirmed;"
"NCI-2015-01745","NCT02797470","A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells","Inclusion/Exclusion","INCLUSION:  HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection  Must be on a multi-drug anti-HIV regimen (excluding zidovudine [AZT, ZDV, Retrovir], or agents containing zidovudine [e.g., Combivir and Trizivir], and efavirenz [Sustiva], or agents containing efavirenz [e.g., Atripla]), and have an HIV-1 viral load < 50 copies/mL by reverse transcriptase-polymerase chain reaction (RT-PCR) at the time of study enrollment; participants on zidovudine ([AZT, ZDV, Retrovir]; including Combivir and Trizivir and efavirenz [Sustiva]; including Atripla) must switch to an alternative regimen without anticipated drug-drug interactions or myelosuppressive properties based on known viral resistance patterns and/or ART history, such as raltegravir and Truvada (emtricitabine and tenofovir) at least two weeks prior to the transplant  EXCLUSION: Any history of HIV-1 associated encephalopathy","HIV=YES AND HAART=YES AND Zidovudine=NO AND Efavirenz=NO AND Viral Load<50 {copies}/mm3 AND AIDS Encephalopathy=NO","C15175=YES AND C94631=YES AND C947=NO AND C29027=NO AND C92544<50 {copies}/mm3 AND C3715=NO","c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c947:affirmed;c947:affirmed;c29027:affirmed;c29027:affirmed;c92544:affirmed;measurement:affirmed;c947:affirmed;c29027:affirmed;"
"NCI-2015-01779","NCT02589522","Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2015-01906","NCT02595866","Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm","Inclusion","Histologically or cytologically proven metastatic or locally advanced tumors for which no standard therapy exists, or where standard therapy has failed, or in patients otherwise ineligible for standard therapy, or for an indication that anti-programmed cell death protein 1 (PD-1) therapy has been shown to be effective in studies in HIV-uninfected participants; disease-specific criteria will be applied for certain common cancers and cancers strongly associated with HIV; however, enrollment will not be confined to these tumors  On an effective combination cART regimen, generally a 3-drug regimen based on Department of Health and Human Services (DHHS) treatment guidelines  * Patients must be on cART >= 4 weeks; and  * Evidence of viral suppression defined as HIV viral load < 200 copies/mL; and   * Most patients have viral loads that are suppressible to < 50 copies/mL, but about 25% of patients will occasionally have blips up to 400â€“500 copies/mL, which do not appear to correlate with lack of viral suppression in most studies; thus, an HIV viral load of =< 400 copies/mL for an occasional â€œblipâ€ will be allowed, if there is documentation of an HIV viral load < 200 on the same regimen and no significant treatment interruption   Total bilirubin < 1.5 X upper limit of normal (ULN); or < 3 x institutional ULN for Gilbertâ€™s syndrome or HIV protease inhibitors; or < 5 x ULN and direct bilirubin < 0.7 mg/dL for patients on atazanavir containing HIV regimen","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=YES and HAART>=4 WEEK AND Viral Load<200 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES C94631>=4 wk AND C92544<200 {copies}/mm3)","c15175:affirmed;measurement:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;c15175:affirmed;c92544:affirmed;measurement:affirmed;measurement:affirmed;measurement:affirmed;c15175:affirmed;c97366:affirmed;measurement:affirmed;measurement:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2015-01907","NCT02595879","Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer","Inclusion/Exclusion:","INCLUSION:  Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following:  * Cluster of differentiation (CD)4+ cell count >= 250/mm^3  * Not on antiretroviral therapy affecting cytochrome P450 (p450) metabolism  * HIV viral loads undetectable by standard clinical tests  EXCLUSION:  Known HIV-positive patients receiving combination antiretroviral therapy are ineligible; however, HIV testing is not required for study enrollment and optional","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=NO AND Cytochrome P450 3A4 Inhibitor=NO AND Viral Load=0 {copies}/mm3 AND CD4>=250 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO AND C111373=NO AND C92544=C111568 {copies}/mm3 AND C103810>=250 {cells}/mm3)","c115935:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;c103810:affirmative;c94631:affirmed;c111374:affirmed;c15175:affirmed;c92544:affirmed;c111568:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2015-01910","NCT02595892","Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2015-01911","NCT02734537","Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing","N/A","","","",""
"NCI-2015-01912","NCT02595905","Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer","N/A","","","",""
"NCI-2015-01913","NCT02595918","A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-metastatic, Renal Cell Carcinoma","Exclusion","Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)","HIV=NO OR HIV=UNKNOWN OR AIDS=NO","C15175=NO OR C15175=C17998 OR C2851=NO","c15175:affirmed;c15175:affirmed;c2851:affirmed;"
"NCI-2015-01915","NCT02595931","Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND CD4=Sufficient AND Viral Load=Acceptable AND (HAART=YES OR cART=YES) AND Cytochrome P450 3A4 Inhibitor=NO AND Cytochrome P450 3A4 Inducer=NO) ","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810=C63351 AND C92544=C63350 AND (C94631=YES) AND C111373=NO AND C111374=NO) ","c15175:affirmed;c15175:affirmed;:affirmed;c92544:affirmed;c94631:affirmed;c1609:affirmed;c97360:affirmed;c29027:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2015-01916","NCT02595944","Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers","Inclusion","Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND (HAART=YES OR cART=YES) AND Viral Load=0 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C94631=YES) AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c141405:affirmed;c92544:affirmed;"
"NCI-2015-01917","NCT02642965","A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)","Inclusion","Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:  * No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3  * No antiretroviral therapy with overlapping toxicity such as myelosuppression  * HIV viral loads below the limit of detection  * No history of highly active antiretroviral therapy (HAART)-resistant HIV","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND AIDS=NO AND Viral Load=0 {copies}/mm3 AND Treatment-sensitive HIV=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C2851=NO AND C92544=C111568 {copies}/mm3 AND Treatment-sensitive HIV=YES)","c15175:affirmed;c15175:affirmed;c15175:affirmed;measurement:affirmed;measurement:affirmed;c94631:affirmed;c15175:affirmed;c92544:affirmed;c94631:affirmed;c15175:affirmed;"
"NCI-2015-01918","NCT02750826","Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer","N/A","","","",""
"NCI-2015-01919","NCT02717455","Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma","N/A","","","",""
"NCI-2015-01929","NCT02601209","A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma","N/A","","","",""
"NCI-2015-02064","NCT02627443","Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer","N/A","","","",""
"NCI-2015-02125","NCT02631733","A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2015-02126","NCT02631746","Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma","Exclusion","Patients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with 3 or more drug anti-retroviral regimen and virus load less than 50 copies/ml and CD4 count greater than 250 cells/ml, and no concurrent opportunistic infection or other malignancy","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=YES AND Viral Load<50{copies}/mm3 AND CD4>250 {cells}/mm3 AND Opportunistic Infection=NO AND Adult T-Cell Leukemia/Lymphoma=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C92544<50{copies}/mm3 AND C103810>250 {cells}/mm3 AND C3289=NO AND C3184=YES)","c15175:affirmed;c15175:affirmed;measurement:affirmed;:affirmed;c3289:affirmed;no:affirmed;c:affirmative;"
"NCI-2015-02248","NCT02890355","Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer","N/A","","","",""
"NCI-2015-02250","NCT02642042","A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies","Inclusion","CLINICAL/LABORATORY CRITERIA: patients must not have a known history of human immunodeficiency virus (HIV) seropositivity","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2015-02253","NCT02823652","COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Test Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling","N/A","","","",""
"NCI-2016-00050","NCT02785952","A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)","Inclusion","Patients must not have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)","HIV=NO OR HIV=UNKNOWN OR AIDS=NO OR AIDS=UNKNOWN","C15175=NO OR C15175=C17998 OR C2851=NO OR C2851=C17998","c15175:affirmed;c15175:affirmed;c2851:affirmed;"
"NCI-2016-00071","NCT03077451","A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma","Exclusion/Inclusion:","EXCLUSION:  Participants receiving any medications or substances that have antiviral activity against KSHV or that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 19 (2C19) are ineligible; the following drugs are also prohibited:  Strong Inhibitors of CYP3A4:  * HIV: non-nucleoside reverse transcriptase inhibitors (delaviridine, nevirapine), protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir), cobicistat-boosted antiretrovirals (e.g., elvitegravir); NOTE: Clinical trials have demonstrated that there are no clinically significant drug-drug interactions between nelfinavir and the following antiretrovirals: efavirenz (strong CYP3A4 inhibitor), etravirine (strong CYP3A4 inhibitor); therefore, these antiretrovirals will not be excluded  INCLUSION:  Known human immunodeficiency virus (HIV)-1 infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site;  HIV seropositive participants must be on antiretroviral therapy (ART) with the following criteria:  * A complete ART regimen that does not include the study drug as one of a minimum of 3 active drugs, which may include an integrase inhibitor or efavirenz in combination with nucleoside reverse-transcriptase inhibitors (NRTIs)  * The ART regimen must not include protease inhibitor (PIs); participants must not have received a PI-based regimen for at least 4 weeks prior to enrollment  * Participants must either have an undetectable HIV plasma ribonucleic acid (RNA), or if plasma RNA detectable, must be on the same stable regimen for a minimum of 12 weeks prior to study enrollment  * No minimum cluster of differentiation (CD)4 count, but maximum HIV plasma RNA of 1,000 copies/mL   ","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Cytochrome P450 2C19 Inducer=NO AND Cytochrome P450 2C19 Inhibotor=NO AND Cytochrome P450 3A4 Inhibitor= NO AND Cytochrome P450 3A4 Inducer= NO AND Non-nucleoside reverse-transcriptase Inhibitors=NO AND HIV Protease Inhibitor=NO AND Cobicistat=NO) AND Viral LOAD<1000 {copies}/mm3)) ","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND Cytochrome P450 2C19 Inducer=NO AND Cytochrome P450 2C19 Inhibotor=NO AND C111373= NO AND C111374= NO AND C97453=NO AND C97366=NO AND C97360=NO) AND C92544<1000 {copies}/mm3)) ","c111374:affirmed;c111374:affirmed;c15175:affirmed;c97453:affirmed;c97366:affirmed;c1609:affirmed;c94631:affirmed;c94631:affirmed;c29027:affirmed;c94631:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;c29027:affirmed;c97366:affirmed;c111568:affirmed;c15175:affirmed;c15175:possible;"
"NCI-2016-00150","NCT02724579","A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients","N/A","","","",""
"NCI-2016-00195","NCT02689453","A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)","Exclusion","Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, hepatitis C  HIV-positive patients are excluded from the study","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;"
"NCI-2016-00203","NCT02713386","A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","Exclusion","Known history of human immunodeficiency virus (HIV),","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2016-00222","NCT02921256","A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer","Inclusion","Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:  * Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy  * Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and  * Have no evidence of opportunistic infections","HIV=NO OR HIV=UNKNOWN OR AIDS=NO OR AIDS=UNKNOWN OR (AIDS=YES AND CD4>=200 {cells}/mm3 AND HAART=NO AND cART=NO AND Opportunistic Infection=NO)","C15175=NO OR C15175=C17998 OR C2851=NO OR C2851=C17998 OR (C2851=YES AND C103810>=200 {cells}/mm3 AND C94631=NO AND C94631=NO AND C3289=NO)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c94631:affirmed;c3289:affirmed;"
"NCI-2016-00232","NCT02717507","Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial","N/A","","","",""
"NCI-2016-00233","NCT02927249","A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial","N/A","","","",""
"NCI-2016-00252","NCT02933489","Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts","N/A","","","",""
"NCI-2016-00264","NCT02728596","A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","N/A","","","",""
"NCI-2016-00325","NCT02728258","A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations","Exclusion","Human immunodeficiency virus (HIV) infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2016-00326","NCT03055013","A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)","Inclusion","No known evidence of human immunodeficiency virus (HIV) infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2016-00355","NCT02723864","Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors","Inclusion","Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-00451","NCT03091660","A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer","N/A","","","",""
"NCI-2016-00456","NCT02839343","Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas","N/A","","","",""
"NCI-2016-00643","NCT02808650","A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors","N/A","","","",""
"NCI-2016-00666","NCT02775851","A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)","Inclusion","Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=350 {cells}/mm3 AND Viral Load<25000 {copies}/mm3 AND (HAART=YES OR cART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=350 {cells}/mm3 AND C92544<25000 {copies}/mm3 AND (C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-00667","NCT02775812","A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)","Exclusion","Severe, active co-morbidity defined as follows:  * Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the cisplatin and IMRT involved in this protocol may be significantly immunosuppressive; patients with known HIV, CD4 counts >= 250/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included  ","HIV=NO OR HIV=UNKNOWN OR AIDS=NO OR AIDS=UNKNOWN OR (HIV=YES AND CD4>=250 {cells}/mm3 AND Viral Load=0 {copies}/mm3","C15175=NO OR C15175=C17998 OR C2851=NO OR C2851=C17998 OR (C15175=YES AND C103810>=250 {cells}/mm3 AND C92544=C111568 {copies}/mm3","c2851:affirmed;c15175:affirmed;c15175:affirmed;c2851:affirmed;c15175:affirmed;:affirmed;c111568:affirmed;c92544:affirmed;c94631:affirmed;"
"NCI-2016-00708","NCT02780804","A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","N/A","","","",""
"NCI-2016-00787","NCT03030417","A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas","Inclusion","Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibiotics","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>350 {cells}/mm3 AND Viral Load=0 {copies}/mm3 AND Prevention and Treatment of Opportunistic Infection =NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>350 {cells}/mm3 AND C92544=C111568 {copies}/mm3 AND C15840=NO)","c15175:affirmed;c15175:affirmed;:affirmed;c111568:affirmed;c92544:affirmed;"
"NCI-2016-00843","NCT03165721","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma Associated with Succinate Dehydrogenase Deficiency and HLRCC-Associated Kidney Cancer","Exclusion","Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation 4 (CD4) count, not requiring antiretroviral medication, may be enrolled","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4=Sufficient {cells}/mm3 AND HAART=NO AND cART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810=C63351 {cells}/mm3 AND C94631=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;c94631:affirmed;"
"NCI-2016-00849","NCT03137771","Maintenance Chemotherapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Chemotherapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial","Exclusion","Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=200 {cells}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=200 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2016-00926","NCT03033992","Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma","N/A","","","",""
"NCI-2016-00927","NCT03041701","A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma","N/A","","","",""
"NCI-2016-00963","NCT03070886","Phase II-III Trial of Adjuvant Radiotherapy following Radical Prostatectomy with or without Adjuvant Docetaxel","Exclusion","Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 1 registration; note also that HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=200 {cells}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=200 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2016-00973","NCT02828358","A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement","N/A","","","",""
"NCI-2016-01040","NCT03141684","A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD4 count > 350 cells/mm^3 with an undetectable viral load","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO AND CD4>350 {cells}/mm3 AND Viral Load=0 {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO AND C103810>350 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;c111568:affirmed;c92544:affirmed;"
"NCI-2016-01041","NCT02834013","DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors","Inclusion","Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:  1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3  2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used  3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts  4. Probable long-term survival with HIV if cancer were not present","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=250 {cells}/mm3 AND Combination Pills with Pharmacologic Boosters=NO AND AIDS=NO AND HEALTHY=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=250 {cells}/mm3 AND Combination Pills with Pharmacologic Boosters=NO AND C2851=NO AND C115935=YES)","c15175:affirmed;c15175:affirmed;:affirmed;c103810:affirmative;measurement:affirmed;measurement:affirmed;c94631:affirmed;c94631:affirmed;c2851:affirmed;:affirmed;:affirmed;c103810:affirmative;c15175:affirmed;"
"NCI-2016-01081","NCT02839707","A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer","Exclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01087","NCT02839720","Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)","Exclusion","Uncontrolled intercurrent illness including, but not limited to, o human immunodeficiency virus (HIV); patients with HIV who have adequate cluster of differentiation (CD)4 counts and who have no requirement for antiviral therapy will be eligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4=Sufficient {cells}/mm3 AND HAART=NO AND cART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810=C63351 {cells}/mm3 AND C94631=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2016-01094","NCT03109301","A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with NF1-Mutated Gastrointestinal Stromal Tumors (GIST)","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND cART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2016-01104","NCT02844816","Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer","Inclusion","Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01105","NCT02887521","Pulmonary Rehabilitation before Lung Cancer Resection","N/A","","","",""
"NCI-2016-01110","NCT02900976","A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-transplant Lymphoproliferative Disease (PTLD)","N/A","","","",""
"NCI-2016-01130","NCT02849496","A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)","Inclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01232","NCT02862275","A Pilot Study of Atezolizumab (MPDL3280A) following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies","Exclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01258","NCT02867592","Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors","N/A","","","",""
"NCI-2016-01300","NCT02879695","A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia","Inclusion","Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:  * They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months  * They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts  * They have an undetectable viral load on standard assays","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HEALTHY=YES AND HAART=YES AND HAART Treatment Duration>6 month AND AIDS=NO AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C115935=YES AND C94631=YES AND C94631>6 mo AND C2851=NO AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c2851:affirmed;c115935:affirmed;c15175:affirmed;measurement:affirmed;:affirmed;:affirmed;c103810:affirmative;c111568:affirmed;c92544:affirmed;"
"NCI-2016-01301","NCT02883062","Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)","Exclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01325","NCT02888743","A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC","Exclusion","Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01326","NCT02890329","A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia","Inclusion","Patients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE AND Prevention and Treatment of Opportunistic Infection =NO AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>250 {cells}/mm3 AND C92544=C111568 AND C15840=NO AND C94631=YES)","c15175:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;c111568:affirmed;c92544:affirmed;c3289:affirmed;c94631:affirmed;"
"NCI-2016-01346","NCT02893917","A Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV-positive patients with undetectable viral loads and CD4 counts > 300, and not on any antiretroviral therapy may be allowed after discussing with the principal investigator","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO AND VIRAL LOAD=UNDETECTABLE AND CD4>300 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO AND C92544=C111568 AND C103810>300 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;c111568:affirmed;c92544:affirmed;:affirmed;c94631:affirmed;"
"NCI-2016-01356","NCT02893930","A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)","Inclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01357","NCT03115333","Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma","N/A","","","",""
"NCI-2016-01363","NCT02899728","A Phase II Study of Olaparib plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01364","NCT02898207","A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=Unknown OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01403","NCT03267433","A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission","Inclusion","Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:  * HIV is sensitive to antiretroviral therapy  * Must be willing to take effective antiretroviral therapy if indicated  * CD4 count at screening >= 300 cells/mm^3  * No history of acquired immune deficiency syndrome (AIDS)-defining conditions","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND Treatment-sensitive HIV=YES AND HAART=YES AND CD4>=300 {cells/mm3} AND AIDS=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND Treatment-sensitive HIV=YES AND C94631=YES AND  C103810>=300 {cells/mm3} AND C2851=NO)","c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;c2851:affirmed;"
"NCI-2016-01412","NCT02975882","A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan","N/A","","","",""
"NCI-2016-01417","NCT02912559","Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair","Inclusion","Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/MM3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND  C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01430","NCT02921269","A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer","Exclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND  C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2016-01461","NCT02923778","A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma","Exclusion","Other viral infections  * Known to have acute or chronic active hepatitis B or hepatitis C infection  * Known to have human immunodeficiency virus (HIV) infection  * Prior therapy with viral-based tumor vaccine  * Received live vaccine within 28 days prior to enrollment  individuals known to have HIV infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c141405:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2016-01494","NCT02981628","A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)","Exclusion","Patients with known human immunodeficiency virus (HIV)","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2016-01501","NCT02936752","A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes after DNA Methyltransferase Inhibitor Therapy Failure","Exclusion","Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul; patients with a known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection might be enrolled if the viral load by PCR is undetectable with/without active treatment","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND (AIDS=YES OR AIDS=NO) AND (Viral Load=UNDETECTABLE {copies}/mm3 AND (HAART=YES OR HAART=NO) AND CD4>=350 {cells}/mm3))","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C2851=YES OR C2851=NO) AND (C92544=C111568 {copies}/mm3 AND (C94631=YES OR C94631=NO) AND  C103810>=350 {cells}/mm3))","c15175:affirmed;c15175:affirmed;c2851:affirmed;c92544:affirmed;c111568:affirmed;c141405:affirmed;c129452:affirmed;c92544:affirmed;c111568:affirmed;"
"NCI-2016-01502","NCT02305654","InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","N/A","","","",""
"NCI-2016-01588","NCT03007147","International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones","N/A","","","",""
"NCI-2016-01595","NCT02954874","A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with â‰¥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy","Inclusion","Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:  * CD4 counts >= 350 mm^3  * Serum HIV viral load of < 25,000 IU/ml and  * Treated on a stable antiretroviral regimen","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=350 {cells}/mm3 AND Viral Load<25000 {copies}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=350 {cells}/mm3 AND C92544<25000 {copies}/mm3 AND C94631=YES)","c141405:affirmed;c129452:affirmed;c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;c15175:affirmed;c92544:affirmed;c94631:affirmed;"
"NCI-2016-01597","NCT03373760","A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)","Inclusion","Patients must not have known human immunodeficiency virus (HIV), or a known positive test for hepatitis B virus surface antigen (HBV sAg), or hepatitis C virus ribonucleic acid (HCV antibody) indicating current acute or chronic infection; patients with a positive hepatitis C antibody with a negative viral load are allowed","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c141405:affirmed;c129452:affirmed;c129452:affirmed;c92544:affirmed;"
"NCI-2016-01619","NCT03180268","Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma","Exclusion","Major medical illnesses or psychiatric impairments, which in the investigators opinion, will prevent administration or completion of the protocol therapy and/or preclude informed consent; these include, but are not restricted to:  * HIV testing is not required for eligibility for this protocol, and known HIV positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 2 registration  ","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND CD4>=200 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND  C103810>=200 {cells}/mm3)","c15175:negated;c15175:negated;c94631:negated;:affirmed;measurement:affirmed;"
"NCI-2016-01698","NCT02965716","A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy","Inclusion","Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV)","HIV=NO OR HIV=UNKNOWN ","C15175=NO OR C15175=C17998 ","c141405:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2016-01733","NCT02971501","A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases","Exclusion","Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy that is a strong inducer CYP3A4; HIV-positive patient not on strong inducers of CYP3A4 are allowed","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND (HAART=NO OR (HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND (C94631=NO OR (C94631=YES AND C111373=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01769","NCT02974621","A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c94631:affirmed;"
"NCI-2016-01771","NCT03274687","A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-prostatectomy Radiation Therapy (COPORT)","Exclusion","Severe, active co-morbidity, defined as follows:  * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol ","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND CD4>=200 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND  C103810>=200 {cells}/mm3)","c15175:affirmed;c15175:affirmed;measurement:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2016-01804","NCT02978625","A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors","Exclusion","Other viral infections:  * Known to have human immunodeficiency virus (HIV) infection  *individuals known to have HIV infection,   ","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2016-01825","NCT03188393","A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery","N/A","","","",""
"NCI-2016-01844","NCT03300544","A Phase I Study of Tailmogene Laheparepvec (Talimogene Laherparepvec) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum","Exclusion"," individuals known to have HIV infection are ineligible  Patients with other viral infections are ineligible:  * Known to have human immunodeficiency virus (HIV) infection","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;c15175:affirmed;"
"NCI-2016-01847","NCT03250299","Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2016-01909","NCT02993146","Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases","Inclusion","Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the study","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=250 {ceslls}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=250 {ceslls}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;measurement:affirmed;"
"NCI-2016-01981","NCT03150693","A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL","N/A","","","",""
"NCI-2016-02009","NCT03186898","A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma","Exclusion","HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=200 {cells}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=200 {cells}/mm3 AND C94631=YES)","c15175:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;:affirmed;measurement:affirmed;c15175:affirmed;"
"NCI-2016-02060","NCT03216499","Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma","Exclusion","Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=NO)","c15175:affirmed;c15175:affirmed;c94631:affirmed;"
"NCI-2017-00009","NCT03269669","Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma","Inclusion"," patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:  * Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low  * Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia* Patient must have serum HIV viral load of < 200 copies/mm^3  * Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)  * Protease inhibitors and once daily formulations containing cobicistat are NOT allowed due to potential pharmacokinetic interactions with leukemia  * Stavudine and zidovudine (AZT) are NOT allowed because of overlapping toxicity with protocol therapy","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND AIDS=NO AND HEALTHY=YES AND VIRAL LOAD<200{copies/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C2851=NO AND C115935=YES AND C92544<200{copies/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;c2851:possible;:possible;c94631:possible;:possible;c115935:possible;c15175:possible;c15175:possible;c92544:possible;measurement:possible;c94631:possible;c97366:possible;c97360:possible;c947:possible;"
"NCI-2017-00058","NCT03018249","A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #26386) Compared to Depo-Provera plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus","N/A","","","",""
"NCI-2017-00105","NCT03033576","A Phase II Randomized Study of Nivolumab (NSC-732442) with Ipilimumab (NSC-748726) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent","Inclusion","Patients with a known history of human immunodeficiency virus (HIV) must have CD4 count >= institutional lower limit of normal within 28 days prior to registration","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=Lower Limit of Normal {cells/mm3})","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=C25555 {cells}/mm3)","c15175:affirmed;c15175:affirmed;:affirmed;c25555:affirmed;"
"NCI-2017-00135","NCT03377556 ","A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)","N/A","","","",""
"NCI-2017-00178","NCT03067181","A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors","N/A","","","",""
"NCI-2017-00203","NCT03180502","A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas","Exclusion","Severe, active co-morbidity defined as follows:  * Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol  ","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=200 {cells}/mm3 AND AIDS=NO)","C15175=NO OR C15175=C17998 OR (C15175=YES AND  C103810>=200 {cells}/mm3 AND C2851=NO)","c15175:affirmed;c15175:affirmed;:affirmed;measurement:affirmed;c2851:affirmed;c15175:affirmed;"
"NCI-2017-00712","NCT03148275","A Non-randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma","Inclusion","Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3)","c15175:affirmed;c15175:affirmed;c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2017-00766","NCT03233204","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes","Exclusion","Patient who are known to be serologically positive for human immunodeficiency virus (HIV)","HIV=NO OR HIV=UNKNOWN","C15175=NO OR C15175=C17998","c15175:affirmed;c15175:affirmed;"
"NCI-2017-01030","NCT03206047","A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer","Exclusion","Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:  * A stable regimen of highly active anti-retroviral therapy (HAART)  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND HAART=YES AND Prevention and Treatment of Opportunistic Infection =NO AND CD4>250 {cells}/mm3 AND VIRAL LOAD=UNDETECTABLE {copies}/mm3)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C94631=YES AND C15840=NO AND C103810>250 {cells}/mm3 AND C92544=C111568 {copies}/mm3)","c15175:affirmed;c15175:affirmed;c94631:affirmed;c3289:affirmed;:affirmed;measurement:affirmed;c111568:affirmed;c15175:affirmed;c92544:affirmed;"
"NCI-2017-01111","NCT03233191","Tomosynthesis Mammographic Imaging Screening Trial (TMIST)","N/A","","","",""
"NCI-2017-01243","NCT03213652","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations","N/A","","","",""
"NCI-2017-01244","NCT03220035","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations","N/A","","","",""
"NCI-2017-01245","NCT03213665","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex","N/A","","","",""
"NCI-2017-01249","NCT03213678","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors","N/A","","","",""
"NCI-2017-01250","NCT03213691","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations","N/A","","","",""
"NCI-2017-01251","NCT03155620","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol","N/A","","","",""
"NCI-2017-01264","NCT03213704","NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions","N/A","","","",""
"NCI-2017-01425","NCT03244384","Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation","Inclusion"," human immunodeficiency virus (HIV) (+) patients are eligible as long as they have: cd4 > 200, undetectable viral load and on highly active antiretroviral therapy (HAART) therapy","HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>200 {cells}/mm3 AND HAART=YES)","C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>200 {cells}/mm3 AND C94631=YES)","c15175:affirmed;c15175:affirmed;:affirmed;c111568:affirmed;c92544:affirmed;c94631:affirmed;"
